Rapport Therapeutics, Inc.RAPP stock score: 32/100
$23.59 · +0.81% · Scored Nov 19, 2026
- Technical
- 26
- Fundamental
- 33
- News
- 51
The reading
Rapport Therapeutics (RAPP) scores 32 out of 100, which reads bearish, higher than 6% of Healthcare stocks and 7% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 33, technicals 26.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while EV/Revenue at 0 weighs the most against it.
On the daily chart, trend-following indicators average 17 and contrarian oscillators 61 — a split worth reading before trusting the technical total.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 30 to 51, and it is down 19 points over the period.
About Rapport Therapeutics
Rapport Therapeutics (RAPP) is a clinical-stage biotechnology company developing drugs for central nervous system disorders. Its approach targets receptor-associated proteins, which help direct how receptors work in specific parts of the brain, with the aim of treating disease while limiting side effects seen with broader-acting drugs. Its lead candidate, RAP-219, is designed to act on AMPA receptors linked to a protein found mainly in brain regions where focal seizures start. RAP-219 is in late-stage trials as an add-on treatment for adults with focal onset seizures, and the company is also studying it in generalized tonic-clonic seizures, bipolar mania and a long-acting injectable form. Rapport has licensed rights to RAP-219 in China to a regional partner. It has no product sales and funds research with cash raised from investors.
In epilepsy, Rapport would compete with established anti-seizure medicines and newer entrants such as SK Biopharmaceuticals’ Xcopri, as well as with candidates from Xenon Pharmaceuticals and other developers. Its edge rests on a precision target that may reduce side effects, a long half-life that may allow simpler dosing and a platform for finding additional neuroscience candidates. Investors who follow RAPP stock tend to watch enrollment and results from the late-stage seizure trials. Data from other indications and long-term safety studies are closely followed. Cash runway, partnering activity and earlier pipeline progress are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward RAPP’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
33Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
EV/Revenue compares the whole company's value, debt included, with its sales.
Price-to-Sales ratio compares market capitalization to annual revenue.
Operating margins measure profitability after operating expenses.
29 weighted scorers; 10 had no data today and are left out rather than counted as zero.
Technical · daily
23Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Holding it back
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
SMA 50 Trend evaluates the slope of the 50-period moving average.
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 37 | 1 |
| Daily | 23 | 3 |
| Weekly | 25 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 32 |
| Nov 18, 2026 | 32 |
| Nov 17, 2026 | 32 |
| Nov 16, 2026 | 33 |
| Nov 15, 2026 | 34 |
| Nov 14, 2026 | 34 |
| Nov 13, 2026 | 34 |
| Nov 12, 2026 | 31 |
| Nov 11, 2026 | 38 |
| Nov 10, 2026 | 36 |
| Nov 7, 2026 | 32 |
| Nov 6, 2026 | 32 |
| Nov 5, 2026 | 32 |
| Nov 4, 2026 | 35 |
| Nov 3, 2026 | 34 |
| Nov 2, 2026 | 33 |
| Nov 1, 2026 | 34 |
| Oct 30, 2026 | 33 |
| Oct 29, 2026 | 32 |
| Oct 28, 2026 | 30 |
| Oct 27, 2026 | 32 |
| Oct 26, 2026 | 33 |
| Oct 25, 2026 | 34 |
| Oct 24, 2026 | 34 |
| Oct 23, 2026 | 33 |
| Oct 22, 2026 | 34 |
| Oct 21, 2026 | 34 |
| Oct 20, 2026 | 36 |
| Oct 19, 2026 | 36 |
| Oct 18, 2026 | 34 |
| Oct 17, 2026 | 34 |
| Oct 16, 2026 | 34 |
| Oct 15, 2026 | 37 |
| Oct 14, 2026 | 35 |
| Oct 13, 2026 | 36 |
| Oct 12, 2026 | 36 |
| Oct 11, 2026 | 37 |
| Oct 10, 2026 | 37 |
| Oct 9, 2026 | 37 |
| Oct 8, 2026 | 36 |
| Oct 7, 2026 | 36 |
| Oct 6, 2026 | 37 |
| Oct 5, 2026 | 38 |
| Oct 4, 2026 | 36 |
| Oct 3, 2026 | 36 |
| Oct 2, 2026 | 37 |
| Oct 1, 2026 | 37 |
| Sep 30, 2026 | 38 |
| Sep 29, 2026 | 37 |
| Sep 28, 2026 | 38 |
| Sep 27, 2026 | 38 |
| Sep 26, 2026 | 38 |
| Sep 25, 2026 | 38 |
| Sep 24, 2026 | 39 |
| Sep 23, 2026 | 41 |
| Sep 22, 2026 | 44 |
| Sep 21, 2026 | 42 |
| Sep 20, 2026 | 43 |
| Sep 19, 2026 | 43 |
| Sep 18, 2026 | 43 |
| Sep 17, 2026 | 44 |
| Sep 16, 2026 | 43 |
| Sep 15, 2026 | 45 |
| Sep 14, 2026 | 46 |
| Sep 13, 2026 | 46 |
| Sep 12, 2026 | 46 |
| Sep 11, 2026 | 46 |
| Sep 10, 2026 | 45 |
| Sep 9, 2026 | 45 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 47 |
| Sep 6, 2026 | 47 |
| Sep 5, 2026 | 47 |
| Sep 4, 2026 | 48 |
| Sep 2, 2026 | 50 |
| Sep 1, 2026 | 50 |
| Aug 31, 2026 | 49 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 48 |
| Aug 27, 2026 | 50 |
| Aug 26, 2026 | 51 |
| Aug 25, 2026 | 51 |
| Aug 24, 2026 | 51 |
| Aug 23, 2026 | 51 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.40
- Risk grade (1–10)
- 7
- Next earnings
- Nov 4, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| QURE uniQure | $1.4B | 45 |
| ABSI Absci | $1.4B | 27 |
| ANAB AnaptysBio | $1.4B | 69 |
| NBTX Nanobiotix | $1.4B | 48 |
| IMCR Immunocore Holdings | $1.4B | 51 |
| TYRA Tyra Biosciences | $1.4B | 31 |
Questions
What is RAPP's stock rating today?
RAPP scores 32/100 (Bearish) as of Nov 19, 2026: technical 26, fundamental 33, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does Rapport Therapeutics do?
Rapport Therapeutics (RAPP) is a clinical-stage biotechnology company developing drugs for central nervous system disorders. Its approach targets receptor-associated proteins, which help direct how receptors work in specific parts of the brain, with the aim of treating disease while limiting side effects seen with broader-acting drugs.
Is RAPP stock a buy?
The score is not a buy or sell recommendation. A 32 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the RAPP score calculated?
91 weighted scorers feed it today: 29 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/rapp/"><img src="https://stocksscores.com/stocks/rapp/badge.svg" alt="RAPP stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/rapp/)